Erastin: Validated Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that induces ferroptosis—iron-dependent, non-apoptotic cell death—by inhibiting the cystine/glutamate antiporter system Xc⁻ and modulating voltage-dependent anion channels (VDACs) (Fan et al., 2024). It is highly selective for tumor cells with RAS or BRAF mutations, making it valuable in cancer biology research. Erastin increases intracellular reactive oxygen species (ROS), leading to lethal oxidative damage. The compound is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with gentle warming. APExBIO’s Erastin (SKU B1524) is widely used for mechanistic studies of oxidative stress and ferroptosis in both engineered and native cell models.

Biological Rationale

Ferroptosis is a regulated, iron-dependent form of cell death distinct from apoptosis, necrosis, and autophagy (Fan et al., 2024). It is characterized by lipid peroxidation and accumulation of ROS. Tumor cells with mutations in the RAS-RAF-MEK signaling pathway, such as KRAS or BRAF, are especially susceptible to ferroptosis. Traditional apoptosis-targeted therapies often fail due to acquired resistance; ferroptosis provides an alternative, caspase-independent death route. Recent studies underscore its significance in overcoming drug resistance and targeting refractory cancer subtypes (Fan et al., 2024).

Mechanism of Action of Erastin

Erastin acts by dual mechanisms:

• Inhibition of system Xc⁻: Erastin blocks the cystine/glutamate antiporter (SLC7A11/xCT), reducing intracellular cystine uptake and depleting glutathione (GSH), a major antioxidant (APExBIO).
• Modulation of VDACs: It modulates voltage-dependent anion channels VDAC2 and VDAC3, promoting mitochondrial oxidative stress and further increasing ROS production (Fan et al., 2024).

This leads to unchecked lipid peroxidation and iron-driven cell death. Erastin’s selectivity for RAS/BRAF-mutant cells arises from their heightened oxidative vulnerability (Related Article – This article expands on the precise redox thresholds exploited by Erastin in mutant cells).

Evidence & Benchmarks

• BRD4 inhibition (via JQ-1/I-BET-762) synergistically enhances Erastin-induced ferroptosis in HEK293T, HeLa, HepG2, RKO, and PC3 cells (Fan et al., 2024).
• Erastin treatment (20 μM, 24–48 h) leads to significant ROS accumulation and cell death in multiple tumor lines (Fan et al., 2024).
• BRD4 knockdown reduces FSP1 expression, further sensitizing cells to Erastin-mediated ferroptosis (Fan et al., 2024).
• Combination treatments targeting both BRD4 and ferroptosis pathways outperform single-agent approaches in FSP1-dependent cells (Fan et al., 2024).
• APExBIO’s Erastin (B1524) is provided as a solid, with solubility of ≥10.92 mg/mL in DMSO, optimal for 10 μM dosing in 24-h cell assays (Product Page).

For a broader discussion of Erastin’s selectivity and application in multidrug-resistant contexts, see this article—the present review updates those findings with new mechanistic data from 2024 studies.

Applications, Limits & Misconceptions

Erastin is a benchmark tool for:

• Dissecting ferroptosis mechanisms in cancer biology research.
• Screening drug candidates targeting iron-dependent, non-apoptotic cell death.
• Modeling oxidative stress and redox signaling in tumor and engineered cell lines.
• Evaluating combinatorial strategies with epigenetic or antioxidant pathway modulators.

Applications extend to understanding resistance in RAS/BRAF-driven tumors and exploring translational potential in oncology (Related article – Unlike reviews that focus only on therapeutic implications, this article provides protocol benchmarks and mechanistic clarity).

Common Pitfalls or Misconceptions

• Erastin does not induce classical apoptosis or necrosis; it is specific for ferroptosis.
• It is not stable in aqueous or DMSO solution for long-term storage; prepare solutions fresh for each experiment (APExBIO).
• Erastin is insoluble in water and ethanol; only DMSO at ≥10.92 mg/mL with warming is suitable for stock solutions.
• Cells lacking iron or with robust antioxidant defenses (e.g., high GPX4/FSP1) may be non-responsive (Fan et al., 2024).
• Results may not extrapolate to non-tumor or primary cells without RAS/BRAF pathway activation.

Workflow Integration & Parameters

APExBIO’s Erastin (B1524) integrates into standard ferroptosis research workflows:

• Preparation: Dissolve Erastin at 10.92 mg/mL in DMSO with gentle warming. Aliquot and store at -20°C.
• Dosing: Typical working concentration is 10 μM in cell culture media; exposure for 24–48 h is standard (APExBIO).
• Controls: Include vehicle (DMSO) and ferroptosis inhibitors (e.g., ferrostatin-1) to validate mechanism.
• Readouts: ROS quantification, lipid peroxidation assays, and cell viability via CCK-8 or propidium iodide staining are recommended (Fan et al., 2024).
• Cell Models: Use in RAS/BRAF-mutant lines (e.g., HT-1080, HEK293T, HeLa) for maximal effect.

For practical guidelines, including troubleshooting and vendor selection, see this guide—here we update protocol recommendations for 2024 reagent batches.

Conclusion & Outlook

Erastin is a rigorously validated ferroptosis inducer with high selectivity for tumor cells harboring RAS/BRAF mutations. Its mechanistic clarity and robust performance in oxidative stress assays have made it a standard reagent in cancer biology research. The latest evidence suggests synergistic potential with BRD4 inhibitors and highlights the importance of redox and iron metabolism in therapy design (Fan et al., 2024). As the field advances, APExBIO’s Erastin will remain integral to dissecting ferroptosis pathways and developing next-generation oncology strategies. For detailed specifications and ordering, see the Erastin product page.